Transcode Therapeutics, Inc. SEC filings RNAZ
Transcode Therapeutics, Inc. has 324 filings in SEC EDGAR's recent list, going back to Dec 18, 2020. Its latest annual report, Form ARS, was filed on Jun 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 17, 2026 | — |
| DEF 14A | Proxy statement | Jun 2, 2026 | Jul 2, 2026 |
| DEFA14A | Additional proxy material | May 26, 2026 | — |
| PRE 14A | Preliminary proxy statement | May 8, 2026 | May 8, 2026 |
| DEFA14A | Additional proxy material | Apr 7, 2026 | — |
| DEFA14A | Additional proxy material | Mar 3, 2026 | — |
| DEFA14A | Additional proxy material | Dec 23, 2025 | — |
| DEFA14A | Additional proxy material | Oct 27, 2025 | — |
| DEFA14A | Additional proxy material | Oct 17, 2025 | — |
| DEFA14A | Additional proxy material | Oct 8, 2025 | — |
| DEFA14A | Additional proxy material | Oct 8, 2025 | — |
| DEF 14A | Proxy statement | Jul 15, 2025 | Aug 29, 2025 |
| DEFA14A | Additional proxy material | Apr 21, 2025 | — |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 11, 2025 | Apr 21, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2025 | Apr 2, 2025 |
| DEFA14A | Additional proxy material | Feb 4, 2025 | — |
| DEF 14A | Proxy statement | Dec 30, 2024 | Feb 4, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 19, 2024 | Feb 28, 2025 |
| DEFA14A | Additional proxy material | Nov 13, 2024 | — |
| DEFA14A | Additional proxy material | Nov 6, 2024 | — |
| DEF 14A | Proxy statement | Oct 28, 2024 | Nov 22, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 15, 2024 | Oct 15, 2024 |
| DEFA14A | Additional proxy material | Jun 10, 2024 | — |
| DEFA14A | Additional proxy material | Jun 7, 2024 | — |
| DEFA14A | Additional proxy material | May 13, 2024 | — |
| PRE 14A | Preliminary proxy statement | May 10, 2024 | Jun 13, 2024 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 13, 2024 |
| DEFA14A | Additional proxy material | Jan 4, 2024 | — |
| DEF 14A | Proxy statement | Dec 18, 2023 | Jan 8, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 8, 2023 | Dec 7, 2023 |
| DEF 14A | Proxy statement | Apr 10, 2023 | May 10, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2023 | May 10, 2023 |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 22, 2022 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNAZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829635
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.